chr21-33243682-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001289125.3(IFNAR2):c.65G>T(p.Ser22Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000229 in 1,613,458 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. S22S) has been classified as Likely benign.
Frequency
Consequence
NM_001289125.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
IFNAR2 | NM_001289125.3 | c.65G>T | p.Ser22Ile | missense_variant | 3/9 | ENST00000342136.9 | |
IFNAR2-IL10RB | NM_001414505.1 | c.65G>T | p.Ser22Ile | missense_variant | 3/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
IFNAR2 | ENST00000342136.9 | c.65G>T | p.Ser22Ile | missense_variant | 3/9 | 1 | NM_001289125.3 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000112 AC: 17AN: 152158Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000716 AC: 18AN: 251390Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135868
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461182Hom.: 0 Cov.: 29 AF XY: 0.00000825 AC XY: 6AN XY: 726964
GnomAD4 genome AF: 0.000112 AC: 17AN: 152276Hom.: 0 Cov.: 32 AF XY: 0.0000806 AC XY: 6AN XY: 74454
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 16, 2022 | The c.65G>T (p.S22I) alteration is located in exon 3 (coding exon 2) of the IFNAR2 gene. This alteration results from a G to T substitution at nucleotide position 65, causing the serine (S) at amino acid position 22 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 09, 2022 | This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 22 of the IFNAR2 protein (p.Ser22Ile). This variant is present in population databases (rs143742626, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with IFNAR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1437130). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at